FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
Phase 2
Completed
- Conditions
- Health Condition 1: null- Acute Adenoviral ConjunctivitisHealth Condition 2: B301- Conjunctivitis due to adenovirus
- Registration Number
- CTRI/2012/06/002727
- Lead Sponsor
- Foresight Biotherapeutics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 308
Inclusion Criteria
Be at least 18 years of age of either sex or any race.
-Have a clinical diagnosis of suspected acute adenoviral conjunctivitis in at least one eye
Exclusion Criteria
Have a known sensitivity to any of the components of FST-100 or FST-100 vehicle.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adenoviral eradication and clinical resolution of the infectionTimepoint: 6-7 days
- Secondary Outcome Measures
Name Time Method Adenoviral eradication and clinical resolution of the infection with FST100 componentTimepoint: 6-7 days